Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Improves Diastolic Dysfunction in Preclinical Nondiabetic Chronic Kidney Disease.

Ixchel Lima-Posada Matthieu Soulie Yohan Stephan Roberto Palacios Ramirez Benjamin Bonnard Lionel Nicol Bertram Pitt Peter Kolkhof Paul Mulder Frédéric Jaisser

Published in: Journal of the American Heart Association (2024)

We showed that the nonsteroidal mineralocorticoid receptor antagonist finerenone reduces renal hypertrophy and albuminuria, attenuates cardiac diastolic dysfunction and cardiac fibrosis, and improves cardiac perfusion in a preclinical nondiabetic CKD model.

Keyphrases

left ventricular
chronic kidney disease
blood pressure
end stage renal disease
oxidative stress
heart failure
cell therapy
ejection fraction
magnetic resonance imaging
computed tomography
mesenchymal stem cells
peritoneal dialysis
bone marrow
atrial fibrillation